Health Catalyst, Inc. (NASDAQ:HCAT) Receives $11.79 Consensus Price Target from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $11.79.

A number of analysts have commented on HCAT shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. JPMorgan Chase & Co. upped their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Royal Bank of Canada lifted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Finally, Citigroup raised their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Insider Transactions at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the transaction, the insider now directly owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the sale, the chief operating officer now directly owns 134,899 shares in the company, valued at $1,036,024.32. This trade represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,551 shares of company stock valued at $532,105 in the last three months. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Quest Partners LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC increased its position in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP raised its holdings in Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. nVerses Capital LLC acquired a new position in Health Catalyst during the 3rd quarter valued at about $59,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Health Catalyst during the 2nd quarter worth approximately $70,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Up 2.8 %

Shares of HCAT stock opened at $7.09 on Friday. The stock has a 50 day moving average of $7.99 and a 200-day moving average of $7.46. The firm has a market cap of $431.41 million, a PE ratio of -5.25 and a beta of 1.31. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period last year, the company earned ($0.22) earnings per share. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, equities analysts predict that Health Catalyst will post -0.33 EPS for the current year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.